Travere Therapeutics, Inc. (TVTX) announced on Tuesday that it has completed a Type C meeting with the FDA regarding its plan to submit an sNDA for FILSPARI for the treatment of focal segmental glomerulosclerosis.
Focal Segmental Glomerulosclerosis or FSGS, a leading cause of kidney failure, currently has no approved pharmacological treatments.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com